Highland Capital Management Fund Advisors, L.P. Biomarin Pharmaceutical Inc Transaction History

Highland Capital Management Fund Advisors, L.P.

$761 Million
Q2 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $373,850 - $427,350	-5,000 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$71.87 - $131.03 $718,700 - $1.31 Million	-10,000 Reduced 66.67%	5,000 $380,000
Q2 2020 Aug 14, 2020	BUY	$79.55 - $124.22 $715,950 - $1.12 Million	9,000 Added 150.0%	15,000 $1.85 Million
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $404,400 - $510,660	6,000 New	6,000 $404,000

Others Institutions Holding BMRN

# of Institutions

632

Shares Held

185M

Call Options Held

1.63M

Put Options Held

1.2M

Black Rock Inc. New York, NY

22.7M
Shares

$1.6 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

19M
Shares

$1.34 Billion
0.03% of portfolio
Primecap Management CO Pasadena, CA

18.8M
Shares

$1.33 Billion
1.14% of portfolio
Dodge & Cox San Francisco, CA

13.9M
Shares

$983 Million
0.72% of portfolio
Capital Research Global Investors Los Angeles, CA

9.69M
Shares

$684 Million
0.18% of portfolio

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Highland Capital Management Fund Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Highland Capital Management Fund Advisors, L.P. with notifications on news.

Account